PRKDC and glioblastoma: Similarly, CC-115 (31), a dual DNA-PK and mTOR inhibitor, has shown potential in certain cancers, achieving stable disease in CRPC and glioblastoma patients, though it was discontinued in glioblastoma trials due to toxicity and limited efficacy.232–239